According to a recently published retrospective analysis in the Journal of Clinical Neurology and Neurosurgery, intravenous (IV) Magnesium therapy provides significant positive outcomes in relieving pain within patients suffered from status migraine.

A total of 234 migraineurs who obtained IV magnesium as a headache abortive were assessed retrospectively. If necessary, additional intramuscular (IM) injections for refractory pain (sumatriptan, dihydroergotamine, ketorolac, dexamethasone) or nausea (metoclopramide, prochlorperazine, ondansetron) were delivered. Self-reported pain levels were measured by applying an 11-point numeric pain rating scale immediately before and following the procedure.

The participants are predominantly females. Thirty-six participants suffered from migraine with aura. After administrating magnesium, overall pain scores were declined from 5.46±2.39 to 3.56 ± 2.75. A total of 127 patients showed clinically significant pain decrease (≥ 30%). One hundred and four patients didn't need supplementary intramuscular (IM) medicines for pain; showed a pain reduction from 4.76 ± 2.41 to 2.95 ± 2.70 and 59% of these patients attained ≥ 30% pain reduction. Participants with less severe pain exhibited a better response as compared to the participants with more severe pain. Hence, IV magnesium may be beneficial as a first-line cost-effective regimen for status migraine management.